WallStSmart
TAK

Takeda Pharmaceutical Co Ltd ADR

NYSE: TAK · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$16.68
+2.33% today

Updated 2026-04-30

Market cap
$52.70B
P/E ratio
75.82
P/S ratio
0.01x
EPS (TTM)
$0.22
Dividend yield
3.96%
52W range
$13 – $19
Volume
2.8M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Takeda Pharmaceutical Co Ltd ADR (TAK) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$16.68
Consensus
$24.00
+43.88%
2030 Target
$22,373.69
+134034.83%
DCF
—
—
17 analysts:
1 Buy0 Hold0 Sell

Management guidance

Takeda announced a transformation program targeting over ¥200 billion (approximately $1.3-1.4 billion USD) in annualized gross savings by FY2028. Management is redirecting these cost savings toward R&D and late-stage pipeline launches (zasocitinib for psoriasis, rusfertide for polycythemia vera, oveporexton for narcolepsy). However, no specific revenue growth targets or absolute revenue guidance through 2030 were disclosed in available materials.

Sources: Management guidance, analyst consensus, sector analysismedium confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$37,288.85
$5890.0B Rev × 20x P/S
Base case (2030)
$22,373.69
$5890.0B Rev × 12x P/S
Bear case (2030)
$14,915.17
$5890.0B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$4027.5B$4263.8B$4581.6B$4630.0B$4850.0B$5180.0B$5520.0B$5890.0B
Revenue growth—5.9%7.5%1.1%4.8%6.8%6.6%6.7%
EPS———$119.00$165.00$210.00$255.00$305.00
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$17,587.49$18,423.29$19,675.13$20,968.19$22,373.69

Catalysts & risks

Growth catalysts
+ Zasocitinib (TYK2 inhibitor) Phase 3 success for psoriasis with NDA filing FY2026 and target launch H1 2027 (peak revenue potential $3-6B)
+ Rusfertide FDA Priority Review for polycythemia vera with PDUFA goal date Q3 2026
+ Oveporexton FDA Priority Review for narcolepsy type 1 with NDA pending 2026
+ Pediatric ENTYVIO Phase 3 success expanding vedolizumab market in children/adolescents
+ $1.3B cost restructuring program generating $200B+ in annual savings by FY2028 to fund pipeline investments
+ Multiple new product launches 2027-2028 offsetting Vyvanse generic competition and patent cliff pressures
Key risks
- Vyvanse patent expiration in 2024-2025 causing significant revenue headwinds (major revenue contributor now at generic risk)
- Trintellix patent losses and generic competition reducing specialty psychiatry revenue base
- Actos RICO class-action lawsuit proceeding to trial with potential multibillion-dollar treble damages exposure
- Massive restructuring program with 634+ U.S. job cuts raising execution risk and potential pipeline delays
- Competitive psoriasis market with multiple oral TYK2 and biologic options already approved (Opdivo, Orencia, Rinvoq)
- FX headwinds from JPY strength eroding USD-reported revenues (50%+ revenue from international markets)
- Regulatory delays or clinical trial setbacks for three transformative launches could materially impact 2027-2028 growth

Methodology

Takeda Pharmaceutical Co Ltd ADR's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 17 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.